trending Market Intelligence /marketintelligence/en/news-insights/trending/e1T9OAgrfl_x_I0p0hs1dA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

TherapeuticsMD prices $71.5M offering to fund product commercialization

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


TherapeuticsMD prices $71.5M offering to fund product commercialization

TherapeuticsMD Inc. priced its underwritten public offering of 26 million common shares at $2.75 per share.

The Boca Raton, Fla.-based company also granted a 30-day option to underwriters to buy up to an additional 3.9 million common shares at the same price.

The company expects $71.5 million in gross proceeds from the offering, assuming no exercise of the underwriters' option. TherapeuticsMD plans to use the net proceeds to commercialize its U.S. Food and Drug Administration-approved products Imvexxy, Bijuva and Annovera.

Imvexxy is used to treat severe dyspareunia — vaginal pain associated with sexual activity — a symptom of vulvar and vaginal atrophy due to menopause. Bijuva is approved for treating moderate to severe vasomotor symptoms, or hot flashes and night sweats, of menopause in women with a uterus. Annovera is a reusable combination hormonal contraceptive ring intended to prevent pregnancy.

J.P. Morgan is acting as sole book-running manager for the offering, while Stifel is acting as lead manager.